Vitrolife Ab · OMXSTO:VITR

Vitrolife Ab — Q1 2026 Earnings Presentation

5 slides from Vitrolife Ab's earnings presentation, 2026

1. Slide 1: Pre-silent call prior to Q1 2026

   Vitrolife AB ( publ) Pre-silent call prior to Q1 2026 Pär Ihrskog, CFO

2. Slide 2: Key factors to consider in Q1 2026

   Key factors to consider in Q1 2026 1. The North America Market: IVF cycle volumes arenormalisingfollowing the White House announcement in October. We expect cycle growth to be back to 2024 levels by mid year. 2. Middle East Crisis:The crisis in the Middle East remains a top priority for us, there is

3. Slide 3: Status Update: Genetic Services Restructuring

   Status Update: Genetic Services Restructuring Vitrolife has completed a strategic review of its genetic services portfolio to enhance focus and profitability. Discontinued Test Lines: • GPDx and NACE fully discontinued by end of March 2026 Restructuring Measures: • Exit from low-profit markets • Aff

4. Slide 4: Reasons to invest in Vitrolife AB (publ)

   Reasons to invest in Vitrolife AB ( publ) Underlying resilient market growth High quality portfoliolinked with outstanding service and support Proven track record of profitable growth Innovation and technology leader within fertility Ambitious strategy and long-term objectives Contact: investors@vit

5. Slide 5: Disclaimer

   Disclaimer This presentation may contain estimates and forward - looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, th

Vitrolife — Q1 2026 Earnings Presentation on 6ix